Ajanta Pharma Share Price
Sector: Biotechnology & Drugs
1298.55 +8.55 (0.66%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1267.15
Today’s High
1305.8
52 Week Low
1112.87
52 Week High
1425.8
1299.30 +6.30 (0.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1287
Today’s High
1307.55
52 Week Low
1111.6
52 Week High
1427.5
Key Metrics
- Market Cap (In Cr) 16280.89
- Beta 0.27
- Div. Yield (%) 0.54
- P/B 4.82
- TTM P/E 26.34
- Peg Ratio 1.12
- Sector P/E 26.15
- D/E 0.01
- Open Price 1267.15
- Prev Close 1290
Ajanta Pharma Analysis
Price Analysis
-
1 Week-0.64%
-
3 Months10.35%
-
6 Month4.94%
-
YTD6.69%
-
1 Year12.13%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 7
- 7
- 7
- 6
- Buy
- 4
- 4
- 3
- 3
- Hold
- 1
- 1
- 2
- 2
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 12
- 12
- 12
- 11
Ajanta Pharma News
Ajanta Pharma share buyback record date set for today. Key details in 5 points
1 min read . 24 Mar 2023Ajanta Pharma share buyback announced. Price, record date, key details to know
1 min read . 10 Mar 2023Ajanta Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2023
- Total Revenue
- 3742.64
- Selling/ General/ Admin Expenses Total
- 785.14
- Depreciation/ Amortization
- 130.8
- Other Operating Expenses Total
- 1123.85
- Total Operating Expense
- 3090.19
- Operating Income
- 652.45
- Net Income Before Taxes
- 745.25
- Net Income
- 587.98
- Diluted Normalized EPS
- 45.89
- Period
- 2023
- Total Assets
- 4679.02
- Total Liabilities
- 1291.03
- Total Equity
- 3387.99
- Tangible Book Valueper Share Common Eq
- 267.53
- Period
- 2023
- Cashfrom Operating Activities
- 791.78
- Cashfrom Investing Activities
- -559.6
- Cashfrom Financing Activities
- -107.87
- Net Changein Cash
- 124.31
- Period
- 2022
- Total Revenue
- 3340.99
- Selling/ General/ Admin Expenses Total
- 1481.72
- Depreciation/ Amortization
- 124.82
- Other Operating Expenses Total
- 35.39
- Total Operating Expense
- 2533.12
- Operating Income
- 807.87
- Net Income Before Taxes
- 909.48
- Net Income
- 712.69
- Diluted Normalized EPS
- 55.44
- Period
- 2022
- Total Assets
- 4055.58
- Total Liabilities
- 791.24
- Total Equity
- 3264.34
- Tangible Book Valueper Share Common Eq
- 251.82
- Period
- 2022
- Cashfrom Operating Activities
- 562.04
- Cashfrom Investing Activities
- -74.1
- Cashfrom Financing Activities
- -460.04
- Net Changein Cash
- 27.9
- Period
- 2021
- Total Revenue
- 2889.69
- Selling/ General/ Admin Expenses Total
- 1171.06
- Depreciation/ Amortization
- 115.6
- Other Operating Expenses Total
- 27.91
- Total Operating Expense
- 2005.01
- Operating Income
- 884.68
- Net Income Before Taxes
- 900.18
- Net Income
- 653.87
- Diluted Normalized EPS
- 50.6
- Period
- 2021
- Total Assets
- 3778.72
- Total Liabilities
- 783.09
- Total Equity
- 2995.63
- Tangible Book Valueper Share Common Eq
- 229.96
- Period
- 2021
- Cashfrom Operating Activities
- 576.31
- Cashfrom Investing Activities
- -282.39
- Cashfrom Financing Activities
- -318.29
- Net Changein Cash
- -24.37
- Period
- 2020
- Total Revenue
- 2587.87
- Selling/ General/ Admin Expenses Total
- 1179.7
- Depreciation/ Amortization
- 95.23
- Other Operating Expenses Total
- 26.25
- Total Operating Expense
- 2004.08
- Operating Income
- 583.79
- Net Income Before Taxes
- 663.97
- Net Income
- 467.7
- Diluted Normalized EPS
- 54.59
- Period
- 2020
- Total Assets
- 3318.69
- Total Liabilities
- 719.82
- Total Equity
- 2598.87
- Tangible Book Valueper Share Common Eq
- 197.66
- Period
- 2020
- Cashfrom Operating Activities
- 456.77
- Cashfrom Investing Activities
- -224.41
- Cashfrom Financing Activities
- -128.63
- Net Changein Cash
- 103.73
- Period
- 2019
- Total Revenue
- 2055.37
- Selling/ General/ Admin Expenses Total
- 842.08
- Depreciation/ Amortization
- 72.08
- Other Operating Expenses Total
- 67.62
- Total Operating Expense
- 1560.79
- Operating Income
- 494.58
- Net Income Before Taxes
- 514.27
- Net Income
- 386.97
- Diluted Normalized EPS
- 29.81
- Period
- 2019
- Total Assets
- 2696.18
- Total Liabilities
- 450.97
- Total Equity
- 2245.21
- Tangible Book Valueper Share Common Eq
- 171.04
- Period
- 2019
- Cashfrom Operating Activities
- 374.78
- Cashfrom Investing Activities
- -222.8
- Cashfrom Financing Activities
- -147.46
- Net Changein Cash
- 4.52
- Period
- 2018
- Total Revenue
- 2130.86
- Selling/ General/ Admin Expenses Total
- 762.34
- Depreciation/ Amortization
- 59.59
- Other Operating Expenses Total
- 85.35
- Total Operating Expense
- 1532.05
- Operating Income
- 598.81
- Net Income Before Taxes
- 622.55
- Net Income
- 468.64
- Diluted Normalized EPS
- 35.97
- Period
- 2018
- Total Assets
- 2448.59
- Total Liabilities
- 407.22
- Total Equity
- 2041.37
- Tangible Book Valueper Share Common Eq
- 154.06
- Period
- 2018
- Cashfrom Operating Activities
- 281.12
- Cashfrom Investing Activities
- -256.11
- Cashfrom Financing Activities
- -0.2
- Net Changein Cash
- 24.81
- Period
- 2023-03-31
- Total Revenue
- 881.84
- Selling/ General/ Admin Expenses Total
- 223.64
- Depreciation/ Amortization
- 33.02
- Other Operating Expenses Total
- 267.93
- Total Operating Expense
- 765.49
- Operating Income
- 116.35
- Net Income Before Taxes
- 152.05
- Net Income
- 122.25
- Diluted Normalized EPS
- 9.54
- Period
- 2023-03-31
- Total Assets
- 4679.02
- Total Liabilities
- 1291.03
- Total Equity
- 3387.99
- Tangible Book Valueper Share Common Eq
- 267.53
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 791.78
- Cashfrom Investing Activities
- -559.6
- Cashfrom Financing Activities
- -107.87
- Net Changein Cash
- 124.31
- Period
- 2022-12-31
- Total Revenue
- 971.77
- Selling/ General/ Admin Expenses Total
- 192.42
- Depreciation/ Amortization
- 33.3
- Other Operating Expenses Total
- 303.48
- Total Operating Expense
- 798.53
- Operating Income
- 173.24
- Net Income Before Taxes
- 168.34
- Net Income
- 134.51
- Diluted Normalized EPS
- 10.5
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 938.1
- Selling/ General/ Admin Expenses Total
- 186.14
- Depreciation/ Amortization
- 32.7
- Other Operating Expenses Total
- 291.97
- Total Operating Expense
- 770.56
- Operating Income
- 167.54
- Net Income Before Taxes
- 203
- Net Income
- 156.6
- Diluted Normalized EPS
- 12.22
- Period
- 2022-09-30
- Total Assets
- 4447.85
- Total Liabilities
- 844.37
- Total Equity
- 3603.48
- Tangible Book Valueper Share Common Eq
- 279.68
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 370.92
- Cashfrom Investing Activities
- -242.62
- Cashfrom Financing Activities
- -7.33
- Net Changein Cash
- 120.97
- Period
- 2022-06-30
- Total Revenue
- 950.93
- Selling/ General/ Admin Expenses Total
- 182.94
- Depreciation/ Amortization
- 31.78
- Other Operating Expenses Total
- 263.36
- Total Operating Expense
- 758.5
- Operating Income
- 192.43
- Net Income Before Taxes
- 221.86
- Net Income
- 174.62
- Diluted Normalized EPS
- 13.63
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 870.29
- Selling/ General/ Admin Expenses Total
- 165.52
- Depreciation/ Amortization
- 31.16
- Other Operating Expenses Total
- 258.76
- Total Operating Expense
- 694.76
- Operating Income
- 175.53
- Net Income Before Taxes
- 197.67
- Net Income
- 151.22
- Diluted Normalized EPS
- 11.66
- Period
- 2022-03-31
- Total Assets
- 4055.58
- Total Liabilities
- 791.24
- Total Equity
- 3264.34
- Tangible Book Valueper Share Common Eq
- 251.82
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 562.04
- Cashfrom Investing Activities
- -74.1
- Cashfrom Financing Activities
- -460.04
- Net Changein Cash
- 27.9
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Ajanta Pharma Technical
Moving Average
SMA
- 5 Day1295.73
- 10 Day1286.24
- 20 Day1283.62
- 50 Day1258.09
- 100 Day1225.34
- 300 Day1248.68
Ajanta Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- IPCA Laboratories
- 685.1
- 1.5
- 0.22
- 1033.5
- 670
- 17381.28
- Glenmark Pharmaceuticals
- 597
- 5.45
- 0.92
- 630
- 348.9
- 16845.55
- Ajanta Pharma
- 1298.55
- 8.55
- 0.66
- 1425.8
- 1112.87
- 16407.18
- J B Chemicals & Pharmaceuticals
- 2108
- 48.3
- 2.35
- 2223.95
- 1339.05
- 16311.19
- Sanofi India
- 6802.2
- -43.15
- -0.63
- 6907.3
- 5079.34
- 15665.89
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- IPCA Laboratories
- 19.36
- 3.15
- 18.3
- 14.45
- Glenmark Pharmaceuticals
- 27.21
- 1.81
- 11.06
- 7.12
- Ajanta Pharma
- 28.13
- 4.81
- 20.33
- 19.22
- J B Chemicals & Pharmaceuticals
- 39.26
- 6.41
- 19.35
- 15.49
- Sanofi India
- 29.55
- 12.23
- 26.62
- 19.61
Ajanta Pharma Shareholding
Shareholding Pattern
*Promoter pledging: 7.68%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 05-May-23
- Audited Results
- 10-Mar-23
- Buy Back of shares
- 01-Feb-23
- Quarterly Results
- 03-Nov-22
- Quarterly Results & Interim Dividend
- 28-Jul-22
- Quarterly Results
- 10-May-22
- Audited Results & Bonus issue
- 31-Jan-22
- Quarterly Results
- 28-Dec-21
- Buy Back of Shares
- 29-Oct-21
- Quarterly Results & Interim Dividend
- 29-Jul-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 11-Mar-23
- 07-Feb-23
- POM
- 04-Aug-22
- 21-Jun-22
- AGM
- 14-Jul-21
- 03-Jun-21
- AGM
- -
- 28-Dec-21
- Others
- -
- 10-Mar-23
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 02-Nov-22
- 14-Nov-22
- 11-Nov-22
- 7
- 21-Oct-21
- 10-Nov-21
- 09-Nov-21
- 9.5
- Announced on
- Record Date
- Ex-Bonus
- Description
- 10-May-22
- 23-Jun-22
- 22-Jun-22
- Bonus issue in the ratio of 1:2 of Rs. 2/-.

